Hypoactive mutations in the PRS (prolyl-tRNA synthetase) domain of EPRS1 lead to hypomyelinating leukodystrophy [181,182] without causing cardiac dysfunction in patients, implying that reduced PRS enzymatic activity does not adversely affect the heart. This evidence concerns the gene EPRS1 and leukodystrophy.